Doxazosin treatment in normotensive and hypertensive patients with benign prostatic hyperplasia

Normotensive (group l) (n-21) and pharmacologically normotensive (group Il) (n=13) patients with benign prostate hypertrophy (BPH) are included in a survey for efficacy of doxazosin, which is a selective alpha-1 bloc-ker. The effects of doxazosin on urinary flow rates, International Prostate Symptom Score (IPSS), residual urine volume and blood pressure are evaluated. Doxazosin was giyen 4 mg for 12 weeks after a titration period of 3 weeks. Differences were found statistically significant in all parameters. In both groups, doxazosin caused a sta-tistically significant reduction in diastolic blood pressure but this was clinically unimportant. Side effects were to-lerated well by the patients. When medical treatment is indicated in normotensive and pharmacologically nor-motensive BPH patients, doxazosin can be used without significant blood pressure reduction.